A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC

Conditions:   Prostate Cancer;   Castration-resistant Prostate Cancer Interventions:   Drug: SHR3680;   Drug: SHR2554 Sponsor:   Jiangsu HengRui Medicine Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials